TECHNESCAN GLUCEPTATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNESCAN GLUCEPTATE (TECHNESCAN GLUCEPTATE).
Technetium-99m glucepstate is a radiopharmaceutical that localizes in renal cortex and urinary tract via glomerular filtration and tubular secretion. In the brain, it accumulates in areas of disrupted blood-brain barrier, such as tumors, infarcts, or abscesses, due to increased vascular permeability and binding to intracellular components.
| Metabolism | Not metabolized; eliminated unchanged by glomerular filtration and tubular secretion. |
| Excretion | Renal: >90% of injected dose excreted via glomerular filtration within 24 hours; biliary/fecal: <5%. |
| Half-life | Terminal elimination half-life: 2-4 hours; allows rapid renal clearance and minimal background interference for imaging. |
| Protein binding | Approximately 10-15% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd: 0.15-0.25 L/kg; reflects distribution primarily into extracellular fluid. |
| Bioavailability | Intravenous: 100% (only route of administration). |
| Onset of Action | Intravenous: Immediate distribution; renal visualization occurs within 5-10 minutes. |
| Duration of Action | Peak renal uptake at 1-2 hours; imaging optimal within 30-60 minutes; minimal activity persists beyond 6 hours. |
For brain imaging: 555-740 MBq (15-20 mCi) intravenously, single dose. For kidney imaging: 111-370 MBq (3-10 mCi) intravenously, single dose.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (GFR <30 mL/min). No specific dose adjustment guidelines; use caution in moderate impairment (GFR 30-60 mL/min). |
| Liver impairment | No specific adjustment for hepatic impairment. Use caution in severe liver disease due to altered metabolism. |
| Pediatric use | Weight-based: 7.4 MBq/kg (0.2 mCi/kg) with minimum 37 MBq (1 mCi) and maximum 555 MBq (15 mCi) for brain imaging; 3.7 MBq/kg (0.1 mCi/kg) for kidney imaging. |
| Geriatric use | No specific dose adjustment required; consider age-related renal decline and monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNESCAN GLUCEPTATE (TECHNESCAN GLUCEPTATE).
| Breastfeeding | No specific M/P ratio available. Technetium-99m has a short half-life (6 hours). After injection, radioactivity appears in breast milk; peak concentration at 1-3 hours. Interrupt breastfeeding for at least 4 hours after administration, preferably longer (e.g., 12-24 hours). Express and discard milk during this period. Alternatively, consider delaying the study until cessation of breastfeeding. |
| Teratogenic Risk | Technetium Tc-99m gluceptate is a radiopharmaceutical. Radiation exposure from diagnostic procedures is generally below threshold for teratogenesis. First trimester: organogenesis period, risk of fetal malformation is dose-dependent; typical administered activity (370-740 MBq) results in fetal absorbed dose <10 mGy, associated with negligible increased risk. Second and third trimesters: risk of stochastic effects (e.g., childhood cancer) increases linearly with dose, but typical doses are low. Avoid unnecessary exposure; consider alternative imaging if possible. |
■ FDA Black Box Warning
Not available (no FDA boxed warning reported for this drug).
| Serious Effects |
["Known hypersensitivity to technetium-99m glucepstate or any component of the formulation","None reported (no absolute contraindications per FDA labeling)"]
| Precautions | ["Risk of anaphylactoid reactions including cardiac arrest and respiratory distress","Hydration status should be assessed before administration to ensure adequate renal function","Use in pregnant women only if clearly needed; consider breast-feeding interruption after administration"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond standard radiation safety precautions. Confirm pregnancy status if unknown. Ensure adequate hydration to promote radiotracer clearance. For fetal exposure, consult nuclear medicine physicist to estimate absorbed dose if needed. |
| Fertility Effects | No known direct effects on fertility at diagnostic doses. High cumulative radiation doses (e.g., repeated exposure) could theoretically affect gonadal function, but typical single diagnostic exposure is well below thresholds. |